(Q44068928)

29 November 2017

Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer (English)

1 reference

29 November 2017

Kollmannsberger C

1

1 reference

29 November 2017

Mayer F

2

1 reference

29 November 2017

Pressler H

3

1 reference

29 November 2017

Koch S

4

1 reference

29 November 2017

Kanz L

5

1 reference

29 November 2017

Oosterhuis JW

6

1 reference

29 November 2017

Looijenga LH

7

1 reference

29 November 2017

Bokemeyer C

8

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

29 November 2017

1 reference

29 November 2017

95

1 reference

29 November 2017

2

1 reference

29 November 2017

301-308

1 reference

Treatment of testicular cancer: a new and improved model

29 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Mechanism of action of anti-HER2 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Differential expression of the c-kit proto-oncogene in germ cell tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Activating c-kit gene mutations in human germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Targeting HER2 in other tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Comparison of different scoring systems for immunohistochemical staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

HER2 as a prognostic and predictive marker for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Signaling--2000 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

Testicular germ-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

7 January 2021

Possible carcinoma-in-situ of the testis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

7 January 2021

Germ cell neoplasms of the testis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

7 January 2021

Results of treatment after relapse from high-dose chemotherapy in germ cell tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

7 January 2021

Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

7 January 2021

Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10671

7 January 2021

Identifiers

DOI

10.1002/CNCR.10671

1 reference

release_ts7qk23vwvahldnm3qijbrhybe

29 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ts7qk23vwvahldnm3qijbrhybe

24 November 2022

mapped directly with Wikidata item

1 reference